Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lexatumumab + PF-573228 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lexatumumab | ETR2-ST01|HGS-1018|HGS-ETR2|HGS1018|TRAIL-R2 | Lexatumumab (ETR2-ST01) is a monoclonal antibody that binds to and activates TRAIL receptor 2, resulting in apoptosis in TRAIL R2-expressing tumor cells (PMID: 17243490, PMID: 23071222). | ||
PF-573228 | PF-573,228|PF573228|PF 573228 | FAK inhibitor 15 | PF-573228 is a small molecule inhibitor of PTK2 (FAK), which may reduce cell migration and decrease focal adhesion cellular turnover, thus suppressing metastasis (PMID: 17395594, PMID: 30352800, PMID: 32349327). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|